Highlight

The potential in esophageal cancer therapy

1. The high EGFR expression in EC

2. Over 50% EC patients have high EGFR expression in the tumor

3. EGFR expression is highly correlated with the EC prognosis

4. High Selectivity to EGFR Kinase

5. Has high selectivity to EGFR Kinase

6. Has considerable inhibitory effect on the EGFR

7. The Special in vivo distribution characteristics

8. Distribute into esophagus tissues (T/B=61) and tumors (T/B=27.4)

Clinical Development Progress

1. Esophageal Carcinoma (EC): Phase Ib/IIa trial finished. Phase III trial, ≥2L, has been started, with first recruitment in November 2020.

2. Pancreatic Cancer: Phase Ib trial started in Nov. 2019. NDA 2024.Q4

3. ORR 20% (10/50) for the EC patients, with better efficacy than Pembrolizumab (ORR 16.7%).

Development Timeline

Expects to file the NDA in China for the first indication, esophageal cancer at the end of 2024 or at the beginning of 2025.

Research progress：

a) The asset expects to file the NDA in China for the first indication, esophageal cancer at the end of 2024 or at the beginning of 2025.